The global genome editing market size was valued at USD 9.9 billion in 2025 and is projected to grow from USD 11.57 billion in 2026 to USD 40.36 billion by 2034, registering a CAGR of 16.9% during the forecast period from 2026 to 2034. North America dominated the genome editing market with a market share of 42.5% in 2025.
Genomic editing refers to the strategies and techniques used to modify the genetic information of any living organism. Genome editing involves the modification of genes in multiple locations using recombinant technology, which increases insertion precision and decreases cell toxicity. It is a collection of technologies that allow scientists to alter an organism's DNA. These technologies enable adding, deleting, or modifying genetic material at specific locations within the genome. Several methods for editing the genome have been developed. CRISPR-Cas9 is a well-known gene-editing system. The CRISPR-Cas9 system is faster, cheaper, more accurate, and more efficient than other genome-editing techniques.
Download a Free Sample To learn more about this report,
Personalized Genome Editing Moves Toward Patient-Specific Treatments
Genome editing is moving beyond standardized therapies toward treatments designed for individual genetic mutations. Advances in CRISPR base editing and delivery technologies are allowing researchers to develop highly targeted medicines for rare diseases that may affect only a small number of patients. Platform-based approaches are important because reusable components can shorten development compared with creating an entirely new technology for every disorder. This trend could broaden genome editing beyond relatively common inherited diseases into ultra-rare conditions that previously lacked commercially practical treatments. Biotechnology companies and research institutions are consequently investing in adaptable editing platforms, delivery technologies, sequencing, and computational tools that support personalized therapeutic development.
In May 2025, NIH-supported researchers reported the first personalized CRISPR-based treatment for a baby with CPS1 deficiency, developed from diagnosis to treatment in about six months.
First Commercial CRISPR Therapy Validates Genome Editing Technology
Commercial availability of CRISPR-based medicines is strengthening confidence in genome editing as a therapeutic platform. Regulatory approvals demonstrate that edited-cell products can progress from laboratory research through clinical trials, manufacturing review, and commercialization. This reduces some technology uncertainty and encourages pharmaceutical companies, biotechnology developers, hospitals, and investors to build capabilities around genome-editing treatments. Commercialization also creates demand beyond editing technology itself, including specialized manufacturing, treatment centers, genetic testing, patient preparation, and long-term monitoring. Expansion into additional countries can gradually build the clinical infrastructure needed for future products, helping genome editing transition from a research-focused field toward an established category of advanced medicines.
In February 2026, Vertex reported that 64 patients received CASGEVY infusions during 2025, while the CRISPR-edited therapy generated USD 116 million in full-year revenue.
Complex Treatment Infrastructure Limits Patient Access
Some genome-editing therapies require highly specialized treatment processes that limit how quickly they can reach patients. Ex-vivo editing can involve collecting a patient's cells, modifying them in controlled manufacturing facilities, conducting quality testing, preparing the patient, and returning the edited cells. Hospitals therefore need specialized teams and infrastructure rather than simply prescribing a conventional medicine. Reimbursement arrangements can create another barrier because health systems must evaluate expensive, potentially one-time therapies differently from recurring treatments. These requirements can slow adoption even after regulatory approval. Genome-editing companies consequently need to establish treatment-center networks, manufacturing capacity, reimbursement agreements, and patient-support systems alongside developing the therapy itself.
In November 2025, Vertex reported that only 39 patients had received CASGEVY infusions globally since launch through September, despite approximately 165 patients having started with first cell collection.
Genome Editing Expands Beyond Rare Diseases into Cardiovascular Care
Genome editing has an opportunity to expand from rare inherited disorders into diseases affecting much larger patient populations. Researchers are evaluating one-time in-vivo editing approaches for cardiovascular conditions by permanently changing genes involved in cholesterol regulation. If these approaches demonstrate durable safety and effectiveness, genome editing could address patients who currently require long-term medication. This would significantly broaden the potential application base for editing platforms and create demand for scalable manufacturing and targeted delivery technologies. Cardiovascular programs also demonstrate how base editing can modify a specific DNA letter without making conventional double-stranded DNA cuts, adding another technology pathway to the genome-editing industry.
In April 2025, Verve Therapeutics reported that VERVE-102 produced a mean LDL-C reduction of 53% in its highest tested dose cohort in the Phase 1b Heart-2 trial.
Off-Target Changes and Long-Term Safety Require Extensive Testing
Ensuring that genome editors modify the intended DNA sequence without causing harmful unintended changes remains a major industry challenge. Because genome alterations can persist for long periods, developers need sensitive methods to identify off-target edits and other changes affecting genome integrity before and during clinical development. Safety evaluation becomes particularly demanding for in-vivo therapies because edited cells cannot simply be removed after treatment. Developers therefore require advanced sequencing, bioinformatics, nonclinical testing, and long-term patient monitoring. These requirements increase development complexity and can affect clinical timelines when safety signals appear, making accurate editing and dependable safety assessment critical factors for broader commercialization.
In July 2026, the U.S. FDA issued draft guidance recommending next-generation sequencing and bioinformatics approaches for assessing off-target editing and genome-integrity risks in human genome-editing therapies.
CRISPR accounted for the largest share of the genome editing market, representing 68.4% of the market in 2025, with a value of USD 6.77 billion, and it is projected to expand at a CAGR of 18.7% during the forecast period. The segment dominates because CRISPR technology offers high precision, faster gene editing, and lower operational costs compared to many traditional genome editing methods. Its broad use in therapeutic development, agricultural biotechnology, and biomedical research continues to strengthen demand. Increasing investments in gene therapy, rising funding for genomic research, and continuous technological improvements are supporting the rapid adoption of CRISPR across academic and commercial applications.
The TALEN and ZFN segments continue to contribute to the genome editing market by serving specialized research and clinical applications. TALEN technology is widely used where highly accurate gene targeting is required, especially in complex genome engineering projects. ZFN remains relevant in selected therapeutic research programs and industrial biotechnology because of its proven performance in specific editing applications. Although these technologies face growing competition from newer editing platforms, ongoing research activities, existing intellectual property portfolios, and demand for alternative genome editing solutions continue to support their presence in the global market.
Request Customizationto receive a tailored report.
Plant Genetic Engineering is projected to register the fastest growth in the genome editing market, expanding at a CAGR of 18.3% during the forecast period. The rapid growth of this segment is driven by increasing efforts to improve crop productivity, enhance resistance to pests and diseases, and develop climate-resilient agricultural products. Growing concerns about global food security and sustainable farming practices are encouraging governments, research institutions, and biotechnology companies to invest in advanced genome editing technologies. The increasing acceptance of gene-edited crops in several countries is also creating favorable opportunities for market expansion.
Cell Line Engineering, Animal Genetic Engineering, and Other Applications continue to play important roles in the market across healthcare, research, and agriculture. Cell line engineering remains widely used in drug discovery, biologics production, and disease modeling due to its critical role in pharmaceutical development. Animal genetic engineering supports biomedical research, livestock improvement, and the development of disease-resistant animal models. Other applications include industrial biotechnology, synthetic biology, and emerging research areas that are benefiting from continuous innovation and expanding genome editing capabilities.
Pharmaceutical and Biotechnology Companies held the largest share of the genome editing market, accounting for 48.6% in 2025, with a market value of USD 4.81 billion, and the segment is expected to grow at a CAGR of 17.9% during the forecast period. The leadership of this segment is supported by increasing investments in gene therapy, precision medicine, and advanced biologics. These companies are actively developing genome editing-based treatments for genetic disorders, cancer, and rare diseases while expanding research partnerships and clinical development programs. Strong financial resources and continuous innovation further strengthen their dominant position in the market.
Academics and Government Research Institutes, Contract Research Organizations, and Other End Users continue to make valuable contributions to the advancement of genome editing technologies. Research institutes play a vital role in discovering new genome editing techniques and expanding scientific knowledge through publicly funded projects. Contract research organizations are gaining importance as pharmaceutical companies increasingly outsource preclinical and clinical research to improve efficiency and reduce development timelines. Other end users, including diagnostic laboratories and specialized research centers, are also supporting market growth by adopting genome editing tools for a wide range of scientific and commercial applications.
Speak to an Analystto discuss market opportunities.
North America dominated the genome editing market with a 42.5% market share in 2025, reaching a market value of USD 4.21 billion, and is projected to grow at a CAGR of 16.1% during the forecast period. The region maintains its leading position because of its strong biotechnology ecosystem, advanced healthcare infrastructure, and high investments in genomic research. The growing adoption of gene editing technologies in drug discovery, precision medicine, and clinical research continues to drive market expansion. Strong collaboration between biotechnology companies, research organizations, and healthcare providers further supports innovation and commercialization, making North America the largest regional market.
The United States is the largest contributor to the North American genome editing market due to its strong presence of biotechnology companies, pharmaceutical manufacturers, and leading academic research institutions. The country continues to invest heavily in gene therapy, precision medicine, and advanced biomedical research, creating favorable conditions for genome editing technologies. Increasing collaboration between universities, healthcare organizations, and private companies accelerates product development and clinical applications. The growing number of research initiatives focused on rare diseases, cancer therapies, and regenerative medicine further strengthens the country's leadership in genome editing innovation.
Canada continues to strengthen its position in the genome editing market through expanding investments in life sciences research and biotechnology innovation. Government-supported research programs, academic collaborations, and a growing biotechnology sector are encouraging the development of advanced genome editing applications. Universities and research centers are actively working on agricultural biotechnology, disease research, and personalized medicine projects. The country's supportive regulatory environment and increasing partnerships between public and private organizations are also helping accelerate scientific discoveries and commercial adoption of genome editing technologies.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific is the fastest-growing region in the genome editing market, accounting for 21.8% of the market in 2025 with a value of USD 2.16 billion, and is expected to expand at a CAGR of 19.4% during the forecast period. Rapid growth is driven by increasing biotechnology investments, expanding healthcare infrastructure, and rising research activities across several countries. Governments are supporting genomic research through funding initiatives while pharmaceutical and biotechnology companies continue to increase research and development activities. Growing awareness of precision medicine and agricultural biotechnology also contributes to the region's strong growth outlook.
Japan plays an important role in the Asia Pacific genome editing market with its well-established biotechnology and pharmaceutical industries. The country focuses on developing innovative therapies for chronic and genetic diseases while promoting advanced biomedical research. Academic institutions and research organizations actively collaborate with industry participants to accelerate scientific discoveries. Japan also emphasizes regenerative medicine and personalized healthcare, creating favorable opportunities for genome editing technologies. Continuous technological innovation and strong research capabilities support the country's long-term development in this market.
China is experiencing rapid progress in the genome editing market due to increasing investments in biotechnology, pharmaceutical research, and healthcare innovation. The country has expanded research activities in gene therapy, agricultural biotechnology, and disease prevention through government-supported initiatives and private sector participation. Collaboration between biotechnology companies and research institutions continues to encourage technological advancements. Growing demand for advanced healthcare solutions, combined with rising scientific capabilities and manufacturing strength, positions China as a significant contributor to the future growth of the genome editing market.
Europe accounted for 27.4% of the genome editing market in 2025, representing a market value of USD 2.71 billion, and is projected to grow at a CAGR of 15.6% during the forecast period. The region benefits from a strong scientific research base, advanced healthcare systems, and increasing investment in biotechnology innovation. Collaboration among research institutes, universities, and pharmaceutical companies continues to accelerate the development of genome editing applications. The growing focus on personalized medicine, rare disease treatment, and sustainable agricultural biotechnology further supports market growth across the region.
Germany remains one of the leading contributors to the European genome editing market because of its advanced biotechnology industry and well-developed pharmaceutical sector. The country has a strong network of research institutions that actively support innovations in molecular biology and genetic engineering. Collaboration between industry and academia encourages the development of new therapeutic applications and research tools. Germany also emphasizes high-quality manufacturing, technological advancement, and scientific excellence, making it an important center for genome editing research and commercialization.
The United Kingdom continues to strengthen its role in the genome editing market through its globally recognized research institutions and active biotechnology ecosystem. Universities, healthcare organizations, and biotechnology companies collaborate extensively to develop innovative gene editing applications for healthcare and life sciences. The country supports scientific innovation through research funding and favorable innovation programs. Increasing interest in precision medicine, advanced diagnostics, and genetic research continues to create new opportunities for genome editing technologies across multiple sectors.
Latin America represented 5.1% of the genome editing market in 2025, with a market value of USD 0.5 billion, and is anticipated to grow at a CAGR of 14.7% during the forecast period. Market growth is supported by expanding biotechnology research, improving healthcare infrastructure, and increasing awareness of advanced genetic technologies. Universities, research organizations, and healthcare providers are gradually adopting genome editing tools for biomedical and agricultural applications. Rising investments in life sciences and growing collaboration with international organizations are expected to strengthen the regional market over time.
Brazil is one of the key contributors to the Latin American genome editing market due to its expanding biotechnology and agricultural research sectors. Research institutions and universities are increasingly exploring genome editing technologies to improve healthcare outcomes and agricultural productivity. The country's strong focus on crop improvement, disease research, and biotechnology innovation supports broader adoption of advanced genetic technologies. Collaboration with international research organizations and increasing investment in scientific infrastructure continue to enhance Brazil's role in regional genome editing development.
The Middle East and Africa accounted for 3.2% of the genome editing market in 2025, reaching a market value of USD 0.32 billion, and is expected to grow at a CAGR of 13.9% during the forecast period. The market is gradually expanding as governments invest in healthcare modernization, biotechnology research, and scientific innovation. Increasing awareness of genetic disorders, growing interest in precision medicine, and improving research capabilities are supporting demand for genome editing technologies. Strategic partnerships and investments in healthcare infrastructure are also contributing to long-term market development.
The United Arab Emirates is emerging as an important market for genome editing through continuous investments in healthcare innovation and biotechnology research. The country is expanding its focus on advanced medical technologies, precision healthcare, and scientific research to improve healthcare quality and encourage innovation. Government initiatives aimed at strengthening biotechnology capabilities and attracting international research collaborations are creating favorable opportunities for genome editing applications. The UAE's commitment to modern healthcare infrastructure and medical research is expected to support the continued adoption of genome editing technologies across healthcare and life sciences.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Europe Tangential Flow Filtration Market Size, Share & Trends | Industry Report, 2034
Asia Pacific Genetic Testing Market Size, 2034
North America TB Diagnostics Market Size & Trends Analysis, 2034
U.S Direct to Consumer Laboratory Testing Market Size, Share and Forecast to 2034
Non-invasive Prenatal Testing Market Size, Share, Growth, 2034
Vaccines Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com